|
Mega Merger
The industry was atwitter with talk of AstraZeneca and BMS merging. Stock prices dropped on the initial news, then jumped when the rumors were denied.
Investors do not seem to be interested in a deal of this size. If it did go through it would create a top 5 colossus.
Rumors like these don't generally come from nowhere, so we will keep our eyes on the situation.
Would be rough to see a merger like this vaporize another 20,000 biopharma jobs.
Cash for Dash
Dash Bio, a noted BioPharmGuy Premium Listing client, has kept their string of success going, this time with a $30M Series A. They've taken the unique path of actually improving how labs work instead of waving their hands and saying “AI” three times.
What’s more, they publish prices on their website. We approve!
Having been a BioPharmGuy client since before their company even launched, is it possible we played a tiny part in this success? Who could really say?
Their COO that’s who:
“Thanks for the support and marketing, it has been really effective and we are excited to keep it going.”
So, are you just gonna keep dumping money into AI advertising forever? Get back to the basics; 45,000 people use the BioPharmGuy directory each month to research biotech-related companies. Check out our ad options.
Oral Gummies
Oral gummies have long solved numerous problems.
Boredom. Nausea. Social anxiety.
Next up? Ebola.
DR Congo's regulatory agency has approved a Phase 2 trial of an oral gummy. Interestingly, this "gummy" does not need to be swallowed and is absorbed in the mouth.
No idea is too crazy for this Ebola outbreak that shows no signs of abating.
Backstock Images
When BioPharmGuy started up back in 2008, it used to be a virtual guarantee that Indian and Chinese companies exclusively used stock images of white Caucasians with occasional Hispanic and African ancestry people peppered in.
Back then, both Asian giants had immature biotech industries, and often tried to present themselves as being US/Europe-adjacent. But also, the readily available stock images in that era were mostly European and American.
It's very rare to see this happen in 2026, but every now and then we come across one. These people kind of don’t look real, but also don’t seem like they’re modern AI stuff.
They all look like professional models except that goofy looking dude in the back middle. What’s going on with that look on his face? Highly punchable.
Prayers, Not Thoughts
Failing phase 3 used to be the end of the line for a potential drug, but companies have been insisting that isn’t true for some years now. Even if a product does eventually get approved post-failure, it can blow up spectacularly like Aduhelm which was ultimately withdrawn from the market by Biogen.
Gossamer Bio is the latest to refuse to read the writing on the wall and will hope the FDA is in an approval-happy mood when they check out the new drug application which includes a failed phase 3 trial.
Re-Petes
Keeping lizards as pets is fun. You can catch bugs, throw them in the cage and watch the lizards pounce.
You can also come up with cute names such as Toothless, Pascal or Scaly. Or Pete.
And if you're like the CEO of EpiCrispr, you can name all your lizards Pete.
Wonder what her husband Peter thinks of this tidbit.
|